XBIO vs CLYM
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 04, 2026
XBIO
41.3
AI Score
VS
CLYM Wins
CLYM
54.3
AI Score
Investment Advisor Scores
CLYM
54score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | XBIO | CLYM | Winner |
|---|---|---|---|
| Net Income | -2.68M | -13.72M | XBIO |
| Operating Income | -2.83M | -15.21M | XBIO |
| ROE | -36.2% | -9.3% | CLYM |
| ROA | -32.1% | -9.0% | CLYM |
| Total Assets | 8.36M | 152.37M | CLYM |
| Cash | 7.88M | 8.36M | CLYM |
| Current Ratio | 8.32 | 27.86 | CLYM |
Relative Price Performance (Last 90 Days)
XBIO 1M: -4.0%
· 3M: -10.4%
CLYM 1M: -8.4%
· 3M: +32.5%
Current Technical Phase
XBIO
NeutralHold
Mixed signals - no dominant trend phase, RSI 46
CLYM
NeutralHold
Mixed signals - no dominant trend phase, RSI 42
Fundamentals Snapshot
| Metric | XBIO | CLYM |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -7.8 | -10.4 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.4% | 0.0% |
| Gross Margin | 1.0% | — |
| Operating Margin | -0.6% | 0.0% |
| EPS | -1.19 | -0.77 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, CLYM is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.